Sanofi Pasteur和Immune Design合作开发生殖器单纯疱疹病毒（HSV）治疗方法

          Sanofi Pasteur和免疫治疗公司Immune Design合作开发生殖器单纯疱疹病毒（HSV）治疗方法。这二家公司目前正尝试不同的免疫药剂组合，以筛选出对患者最有效的免疫治疗方案。

同时，这二家公司都将继续各自的候选疫苗的研究。 Sanofi 将对其研发的复制缺陷型HSV候选疫苗HSV-529进行后期的临床试验。Immune Design也将深入其候选疫苗G103的研发。

Sanofi和Immune Design 将合作进行疫苗的二期临床试验。其中，Sanofi将承担临床前期和临床研发的所有费用。而Immune Design将会对试验中出现的问题，以及疫苗的改造提供更为详细和可靠的方案。（转化医学网360zhyx.com）

原文：Sanofi Pasteur, Immune Design to Develop HSV Therapy

· Sanofi Pasteur is teaming up with immunotherapy company Immune Design to develop a herpes simplex virus (HSV) immune therapy. The firms plan to explore different combinations of agents, including leveraging Immune Design’s GLAAS™ drug discovery platform, with the aim of selecting the best potential immune therapy for patients.

Both firms will be contributing candidates as part of this collaboration: Sanofi Pasteur will contribute its clinical-stage replication-defective HSV vaccine candidate HSV-529, and Immune Design will contribute G103, a preclinical trivalent vaccine candidate.

The two companies are planning to develop the products jointly through Phase II trials, at which point Sanofi Pasteur will continue developing the most promising candidate and will be in charge of commercialization; the firm will also pay for all preclinical and clinical development. Meanwhile, Immune Design will provide a specific formulation of glucopyranosyl lipid adjuvant (GLA) from the GLAAS platform at its cost through Phase II studies. Immune Design says it will be eligible to receive future milestone and royalty payments on any product developed from the collaboration.